Central Nervous System Diseases Clinical Trials
2 recruiting trials for Central Nervous System Diseases. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Central Nervous System Diseases clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Advanced Technology & Communications (1), Insel Gruppe AG, University Hospital Bern (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is ATNC MDD-V1 (Real TMS + Real Cog) (device, 1 trial), followed by ATNC MDD-V1 (Sham TMS + Real Cog), ATNC BN-V1.
Track Central Nervous System Diseases trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.
Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Central Nervous System Diseases, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Central Nervous System Diseases, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Central Nervous System Diseases, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.